| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |